4BIO portfolio company Orchard Therapeutics Announces $150 Million Series C Financing

Orchard Therapeutics, a leading commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the completion of an oversubscribed $150 million Series C financing. Read more at Globe Newswire.

ARCHIVE
SEARCH BY TAGS
FOLLOW US
4BIO CAPITAL is a trade name of 4BIO Ventures Management Ltd, which is authorised and regulated by the Financial Conduct Authority, register number 775193
© 2015-2020 by 4BIO Ventures Management Ltd